All In Biotech

Drug Trial Radar · NCT05479812

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

156

Actual

Start

Aug 15, 2022

Primary completion

Apr 22, 2026

Study completion Apr 22, 2026

Sponsor

Lead sponsor
Werewolf Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.

Conditions

  • Metastatic Solid Tumor
  • Advanced Solid Tumor

Interventions

  • WTX-124Drug

    Investigation Product Monotherapy

  • pembrolizumabDrug

    Investigation Product in combination with approved therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapyTime frame: 4 weeks
  2. Incidence of treatment emergent adverse events in monotherapy and combination therapyTime frame: 24 months
  3. Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapyTime frame: 24 months
  4. Dose Expansion - Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapyTime frame: 4 weeks
  5. Dose Expansion - Incidence of treatment emergent adverse events in monotherapy and combination therapyTime frame: 24 months
  6. Dose Expansion - Incidence of changes in clinical laboratory abnormalities in monotherapy and combination therapyTime frame: 24 months
  7. Dose Expansion - Investigator-assessed objective response rate (ORR) per RECIST 1.1 and iORR by iRECIST in monotherapy and combination therapyTime frame: 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana

  • Minnesota Oncology Hematology, P.A.

    Maple Grove, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Comprehensive Cancer Care

    Buffalo, New York

  • Westchester Medical Center

    Hawthorne, New York

  • Providence Cancer Institute Franz Clinic

    Portland, Oregon

  • Texas Oncology - Austin Midtown

    Austin, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • NEXT Oncology

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.